VTYX Ventyx Biosciences, Inc.


$ 9.37 $ -0.18 (-1.87 %)    

Friday, 21-Nov-2025 15:55:00 EST
QQQ $ 590.50 $ 4.40 (0.75 %)
DIA $ 462.65 $ 5.05 (1.1 %)
SPY $ 658.99 $ 6.50 (1 %)
TLT $ 89.49 $ 0.27 (0.3 %)
GLD $ 373.73 $ -0.58 (-0.15 %)
$ na
$ 9.52
$ 9.42 x 205
$ 9.39 x 59
$ 8.90 - $ 9.58
$ 0.78 - $ 10.02
1,823,700
na
685.76M
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-ventyx-biosciences-raises-price-target-to-16

Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and raises the price target from...

 wells-fargo-maintains-overweight-on-ventyx-biosciences-raises-price-target-to-14

Wells Fargo analyst Derek Archila maintains Ventyx Biosciences (NASDAQ:VTYX) with a Overweight and raises the price target f...

 hc-wainwright--co-upgrades-ventyx-biosciences-to-buy-announces-18-price-target

HC Wainwright & Co. analyst Emily Bodnar upgrades Ventyx Biosciences (NASDAQ:VTYX) from Neutral to Buy and announces $18...

 oppenheimer-maintains-outperform-on-ventyx-biosciences-raises-price-target-to-14

Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and raises the price target from...

 ventyx-stock-is-rallying-thursday-whats-driving-the-surge

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for...

 why-ventyx-vtyx-shares-soared-865-after-hours

Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results.

 ventyx-biosciences-announces-positive-results-from-phase-2-trial-of-vtx3232-for-obesity-cardiovascular-risk-factors-vtx3232-monotherapy-achieved-80-reduction-in-hscrp-vtx3232-monotherapy-reduced-il-6-levels

Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), today announced positive results from its Phase ...

 clear-street-initiates-coverage-on-ventyx-biosciences-with-buy-rating-announces-price-target-of-11

Clear Street analyst Kaveri Pohlman initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces P...

 ventyx-biosciences-q2-eps-038-beats-045-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION